Get the content you want anytime you want.
The Best Infectious Disease News Delivered Weekly

The Contagion® Sexually Transmitted Diseases (STD) specialty page provides STD-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


Who is the Target Population for Cabotegravir?
Alex Rinehart, PhD, identifies the target population for cabotegravir.
Why is the Population-based HIV Impact Assessment Project Important?
Jessica Justman, MD, shares why the Population-based HIV Impact Assessment Project is so important.
Is Cabotegravir a Gender-Neutral PrEP Medication?
Alex Rinehart, PhD, explains how cabotegravir is a gender-neutral pre-exposure prophylaxis medication.
Societal Challenges Keep At-risk Individuals from Taking PrEP
Kenneth Mayer, MD, discusses some societal challenges that at-risk individuals face today that may keep them from taking pre-exposure prophylaxis.
What is the Population-based HIV Impact Assessment Project?
Jessica Justman, MD, explains the PHIA Project (population-based HIV impact assessments).
How is Janssen's New HIV-1 Vaccine Regimen Unique?
Hanneke Schuitemaker, PhD, explains what makes Janssen’s new HIV-1 vaccine regimen unique.
What Makes Cabotegravir a Unique Medication for HIV?
Alex Rinehart, PhD, Director, Global Prevention Strategy, ViiV Healthcare, explains what makes cabotegravir a unique medication for HIV.
How Can Primary Care Providers Help Their Patients Decide if PrEP Is Right for Them?
Kenneth Mayer, MD, explains why primary care providers need to have a good sense of their patients in order to help them decide if PrEP is right for them.
We break down our top HIV news stories of 2017. Did you read them all?